~~<i id='124CAE7B1B'><strike id='124CAE7B1B'><tt id='124CAE7B1B'><pre id='124CAE7B1B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：knowledge 2025-09-28 23:49:13 - browse：96

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： FDA poised to publish guidelines for clinical trial diversity

leisure time

entertainment

knowledge

leisure time

hotspot

leisure time

1:21Thebeachisclosed.Thesignreads"Notice:thisbeachareamaynotbesuitableforswimmingduetohighlevelsofba

WSS

ACA's risk program benefits Blue Cross Blue Shield insurers

Eyeing GLP

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Investigation reveals sickle cell patients pressured into sterilizations

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Recent heat wave in the Mediterranean caused by climate change: Study

knowledge

comprehensive

leisure time

Psychedelics group wrestles with new pharma identity

Biogen joins immunology wave with $1.15 billion acquisition of HI

Virginia high school admissions case could be legal follow

ASCO eve: Let’s set the table for this year's meeting

Hepatitis C has a cure — but many Americans still lack access to it

Eisai exec who led development of Alzheimer’s drug to retire

Peter Hotez and the public health issue of online harassment

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Activists slam private health insurers over coverage restrictions

Cue Health, Covid

entertainment

Pandemic and All Hazards Preparedness Act needs lean update

Eyeing GLP

Bird flu surveillance in wastewater gets boost from consortium

Making the case for fair compensation in clinical trials

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

Home health providers sue Medicare over payment cuts

knowledge

leisure time

hotspot

leisure time